From: Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease
Qualitative variables | n | Â | Pvalue |
---|---|---|---|
  Female | 102 |  | .22 |
  ∆F508 homozygous mutation | 79 |  | .02 |
  Exocrine pancreatic insufficiency | 102 |  | .55 |
  Pseudomonas aeruginosa | 99 |  | .36 |
Quantitative variables | n | Correlation (r) | |
  Age, years | 102 | −0.11 | .29 |
  BMI, kg/m2* | 102 | 0.26 | .009 |
  Leukocytosis, 109/mm3 | 70 | −0.42 | .0003 |
  CRP, mg/L | 64 | −0.34 | .006 |
  Serum albumin, g/L | 43 | 0.34 | .02 |
  FEV1 a* | 102 | 0.71 | < .0001 |
  FVCa* | 102 | 0.69 | < .0001 |
  RVa | 79 | −0.58 | < .0001 |
  DLCOa | 68 | 0.56 | < .0001 |
  PaO2, mm Hg | 98 | 0.43 | < .0001 |
  PaCO2, mm Hg | 98 | 0.11 | .29 |
Cardiopulmonary exercise parameters | n | Correlation (r) | |
  VE peak, L | 102 | 0.64 | < .0001 |
  VE/VCO2 peak* | 98 | −0.35 | < .0001 |
  BR, %* | 102 | 0.37 | .0001 |
  VD/VT peak* | 96 | −0.64 | < .0001 |
  PaCO2 peak, mm Hg* | 97 | −0.45 | < .0001 |
  P(A-a)O2 peak, mm Hg* | 97 | −0.54 | < .0001 |
  Lactatemia peak, mmol/L* | 86 | 0.59 | < .0001 |
  HR peaka | 102 | 0.40 | < .0001 |